Trial Profile
A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis (PAR)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Oct 2023
Price :
$35
*
At a glance
- Drugs Fluticasone furoate (Primary)
- Indications Perennial allergic rhinitis
- Focus Adverse reactions
- Acronyms AVY-REG00108VN
- Sponsors GlaxoSmithKline; GSK
- 08 Jan 2011 New trial record